Reference health
Pathogenesis of Hypertension
102/102 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
9 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 102 checked references that resolve
resolves10.1056/NEJMra011078
Subtle Acquired Renal Injury as a Mechanism of Salt-Sensitive Hypertension
resolves10.1093/oxfordjournals.aje.a112464
THE NHLBI TWIN STUDY OF CARDIOVASCULAR DISEASE RISK FACTORS: METHODOLOGY AND SUMMARY OF RESULTS
resolves10.1093/oxfordjournals.aje.a113862
ENVIRONMENTAL AND GENETIC SOURCES OF FAMILIAL AGGREGATION OF BLOOD PRESSURE IN TECUMSEH, MICHIGAN
resolves10.1161/01.CIR.101.24.2810
QTL Influencing Blood Pressure Maps to the Region of
<i>PPH1</i>
on Chromosome 2q31-34 in Old Order Amish
resolves10.1161/01.HYP.33.6.1324
Seven Lessons From Two Candidate Genes in Human Essential Hypertension
resolves10.1097/00004872-199917010-00003
M235T angiotensinogen gene polymorphism and cardiovascular renal risk
resolves10.1161/01.CIR.97.18.1773
Variation in the Region of the Angiotensin-Converting Enzyme Gene Influences Interindividual Differences in Blood Pressure Levels in Young White Males
resolves10.1161/01.CIR.97.18.1766
Evidence for Association and Genetic Linkage of the Angiotensin-Converting Enzyme Locus With Hypertension and Blood Pressure in Men but Not Women in the Framingham Heart Study
resolves10.1016/0092-8674(94)90250-X
Liddle's syndrome: Heritable human hypertension caused by mutations in the β subunit of the epithelial sodium channel
resolves10.1161/01.HYP.31.5.1118
Mutations and Variants of the Epithelial Sodium Channel Gene in Liddle’s Syndrome and Primary Hypertension
resolves10.1152/ajpcell.2001.281.5.C1413
Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy
resolves10.1056/NEJM199807233390404
Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial Infarction
resolves10.1056/NEJM199602083340607
Hypertension and Associated Metabolic Abnormalities — The Role of Insulin Resistance and the Sympathoadrenal System
resolves10.1097/00000441-198804000-00019
Mechanisms of Resetting of Arterial Baroreceptors: An Overview
resolves10.1161/01.RES.53.2.223
Arterial baroreflexes in renal hypertensive rabbits. Selectivity and redundancy of baroreceptor influence on heart rate, vascular resistance, and lumbar sympathetic nerve activity.
resolves10.1172/JCI114754
Mechanism of decreased baroreceptor activity in chronic hypertensive rabbits. Role of endogenous prostanoids.
resolves10.1161/01.HYP.17.1.72
Rapid baroreceptor resetting in chronic hypertension. Implications for normalization of arterial pressure.
resolves10.1161/01.RES.79.4.802
Oxygen-Derived Free Radicals Contribute to Baroreceptor Dysfunction in Atherosclerotic Rabbits
resolves10.1161/01.HYP.11.6.608
Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects.
resolves10.1161/01.CIR.90.2.928
Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study.
resolves10.1161/01.HYP.26.2.348
Sympathetic Modulation of Radial Artery Compliance in Congestive Heart Failure
resolves10.1152/physrev.1990.70.4.963
Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions
resolves10.1042/cs057197s
Recordings of Renal and Splanchnic Sympathetic Nervous Activity in Normotensive and Spontaneously Hypertensive Rats
resolves10.1161/01.HYP.22.6.801
Normotensive blacks have heightened sympathetic response to cold pressor test.
resolves10.1097/00041552-200109000-00011
Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy?
resolves10.1161/01.HYP.25.4.474
Effect of Antihypertensive Treatment on Small Arteries of Patients With Previously Untreated Essential Hypertension
resolves10.3109/10641969609088965
The Evidence for a Pathophysiologic Significance of the Sympathetic Overactivity in Hypertension
resolves10.1161/01.HYP.36.1.142
Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats
resolves10.1152/ajprenal.2000.278.5.F769
Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR
resolves10.1097/00004872-198811000-00001
On the renal basis for essential hypertension: nephron heterogeneity with discordant renin secretion and sodium excretion causing a hypertensive vasoconstriction-volume relationship
resolves10.1016/S0022-2143(96)90117-1
Renal function reserve and sodium sensitivity in essential hypertension
resolves10.1161/01.HYP.34.1.144
Serum Uric Acid and Cardiovascular Events in Successfully Treated Hypertensive Patients
resolves10.7326/0003-4819-131-1-199907060-00003
Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study
resolves10.7326/0003-4819-93-6-817
Serum Uric Acid in Essential Hypertension: An Indicator of Renal Vascular Involvement
resolves10.1111/j.1532-5415.1978.tb02396.x
Serum Uric Acid and the Renin‐Angiotensin System in Hypertension
resolves10.1097/00004872-200018080-00021
Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP)
resolves10.1161/hy1101.092839
Elevated Uric Acid Increases Blood Pressure in the Rat by a Novel Crystal-Independent Mechanism
resolves10.1152/ajprenal.00283.2001
Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism
resolves10.1016/S0021-9258(18)93017-6
Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression
resolves10.1161/01.RES.18.3.263
Comparative Changes in Segmental Vascular Resistance in Response to Nerve Stimulation and to Norepinephrine
resolves10.1016/S0895-7061(97)88656-6
Reduction of wave reflection is the principal beneficial action of felodipine in isolated systolic hypertension
resolves10.1016/S0140-6736(99)07330-4
Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials
resolves10.1001/jama.288.12.1491
Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy
resolves10.1177/00912709922008155
Practical Considerations of the Pharmacology of Angiotensin Receptor Blockers
resolves10.1161/01.HYP.35.5.1069
Proapoptotic and Growth-Inhibitory Role of Angiotensin II Type 2 Receptor in Vascular Smooth Muscle Cells of Spontaneously Hypertensive Rats In Vivo
resolves10.1210/er.2003-0001
Newly Recognized Components of the Renin-Angiotensin System: Potential Roles in Cardiovascular and Renal Regulation
resolves10.1161/01.RES.80.1.45
p22phox mRNA Expression and NADPH Oxidase Activity Are Increased in Aortas From Hypertensive Rats
resolves10.1172/JCI118623
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
resolves10.1089/ars.1999.1.2-167
Arachidonic Acid Metabolites Mediate Angiotensin II-Induced NADH/NADPH Oxidase Activity and Hypertrophy in Vascular Smooth Muscle Cells
resolves10.1161/01.RES.83.9.952
Angiotensin II Induces Monocyte Chemoattractant Protein-1 Gene Expression in Rat Vascular Smooth Muscle Cells
resolves10.1161/01.CIR.100.11.1223
Angiotensin II Induces Vascular Cell Adhesion Molecule-1 Expression In Rat Vasculature
resolves10.1056/NEJM200001203420301
Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
resolves10.1056/NEJMoa021716
A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly
resolves10.1016/S0140-6736(02)08089-3
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
resolves10.1056/NEJMoa011161
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
resolves10.1056/NEJMoa011303
Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes
resolves10.1056/NEJMoa011489
The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
resolves10.1001/jama.289.19.2560
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>
resolves10.1097/00004872-200306000-00001
2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*
resolves10.1016/S0140-6736(02)08090-X
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
resolves10.1001/jama.288.23.2981
Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
resolves10.1056/NEJM199909023411001
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
resolves10.1056/NEJMoa030207
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
resolves10.1161/01.HYP.0000040261.30455.B6
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension
resolves10.1161/01.RES.87.10.840
Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress
resolves10.1161/01.CIR.95.3.588
Role of Superoxide in Angiotensin II–Induced but Not Catecholamine-Induced Hypertension
resolves10.1161/01.HYP.28.4.652
Racial Differences in Plasma Endothelin-1 Concentrations in Individuals With Essential Hypertension
resolves10.1056/NEJM199803193381202
The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension
resolves10.1016/S0140-6736(01)06250-X
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
resolves10.1056/NEJMoa010273
Characteristics of Patients with Uncontrolled Hypertension in the United States
The 9 references without a DOI — listed, not checked
no DOI — not checkedr8-11
no DOI — not checkedr28-11
no DOI — not checkedr36-11
no DOI — not checkedr37-11
no DOI — not checkedr38-11
no DOI — not checkedr40-11
no DOI — not checkedr57-11
no DOI — not checkedr101-11
no DOI — not checkedr118-11
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.7326/0003-4819-139-9-200311040-00011"><img src="https://citestamp.com/citestamped/10.7326/0003-4819-139-9-200311040-00011/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.7326/0003-4819-139-9-200311040-00011)